Brokerages Set Senseonics Holdings, Inc. (NYSE:SENS) Target Price at $22.70

Senseonics Holdings, Inc. (NYSE:SENS) has been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, three have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $22.70.

A number of research firms have weighed in on SENS. Barclays reiterated an “overweight” rating and set a $31.00 price target (up previously from $1.50) on shares of Senseonics in a research note on Wednesday, November 5th. TD Cowen reiterated a “buy” rating on shares of Senseonics in a research report on Thursday, January 8th. Finally, HC Wainwright increased their price target on shares of Senseonics to $18.50 and gave the stock a “buy” rating in a research report on Thursday, November 6th.

Senseonics Price Performance

Shares of NYSE:SENS opened at $8.16 on Wednesday. The firm has a market capitalization of $333.41 million, a PE ratio of -62.77 and a beta of 0.99. The company has a current ratio of 2.47, a quick ratio of 2.38 and a debt-to-equity ratio of 59.17. Senseonics has a 1-year low of $5.25 and a 1-year high of $22.10. The business’s 50 day moving average is $6.94 and its 200-day moving average is $7.66.

Hedge Funds Weigh In On Senseonics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its position in Senseonics by 26.2% in the first quarter. Goldman Sachs Group Inc. now owns 612,534 shares of the company’s stock valued at $402,000 after acquiring an additional 127,086 shares during the period. Elite Life Management LLC bought a new stake in shares of Senseonics in the 2nd quarter worth about $36,000. Keynote Financial Services LLC increased its position in shares of Senseonics by 1,120.2% during the 2nd quarter. Keynote Financial Services LLC now owns 208,285 shares of the company’s stock worth $99,000 after purchasing an additional 191,215 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Senseonics by 26.6% during the 2nd quarter. Geode Capital Management LLC now owns 8,701,129 shares of the company’s stock worth $4,147,000 after purchasing an additional 1,828,302 shares in the last quarter. Finally, Sio Capital Management LLC bought a new position in Senseonics during the 2nd quarter valued at about $2,312,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.